Understanding of MLL-related leukemogenesis and identification of new therapeutic targets

2016 Fiscal Year Final Research Report

• Project/Area Number: 15K19601
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Pediatrics
• Research Institution: Tokyo Medical and Dental University
• Principal Investigator: Aoki Yuki 東京医科歯科大学, 医学部附属病院, 非常勤講師 (90706839)
• Research Collaborator: TAKAGI Masatoshi 東京医科歯科大学, 茨城県小児・周産期地域医療学講座, 准教授 (10406267)
• Project Period (FY): 2015-04-01 – 2017-03-31
• Keywords: NSGマウス / 異種移植 / MLL / ALL / DNA修復機構

Outline of Final Research Achievements

MLL-rearranged infantile acute lymphocytic leukemia (ALL) is a disease with poor prognosis and establishment of a novel treatment method is desired. We developed a treatment method by drug administration in vivo using a leukemia transplantation model for NSG immunodeficient mouse into which human cells can be transplanted. ALL-derived cell (HAL-01) when transplanted into NSG mouse and treated dose of anthracycline anticancer drug doxorubicin which induces DNA damage, NSG mouse is deficient in Prkdc and disrupted non-homologous end joining (NHEJ), because of its toxicity, he died soon. When cyclosporin, a drug transport pump (p-gp) inhibitor, was used in combination, the survival rate of leukemia transplanted mice was prolonged.

Free Research Field

小児血液・腫瘍